Morgan Stanley Evaxion Biotech A/S Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$1.12 - $1.74 $36,723 - $57,052	-32,789 Reduced 90.49%	3,446 $4,000
Q1 2023 May 15, 2023	BUY	$1.03 - $1.8 $33,515 - $58,570	32,539 Added 880.38%	36,235 $40,000
Q3 2022 Nov 14, 2022	SELL	$1.9 - $27.7 $1,140 - $16,620	-600 Reduced 13.97%	3,696 $10,000
Q2 2022 Oct 27, 2022	SELL	$1.6 - $3.07 $6,497 - $12,467	-4,061 Reduced 48.59%	4,296 $8,000
Q2 2022 Aug 15, 2022	SELL	$1.6 - $3.07 $6,497 - $12,467	-4,061 Reduced 48.59%	4,296 $8,000
Q1 2022 Oct 27, 2022	BUY	$2.66 - $4.65 $10,802 - $18,883	4,061 Added 94.53%	8,357 $26,000
Q1 2022 May 13, 2022	BUY	$2.66 - $4.65 $12,398 - $21,673	4,661 Added 126.11%	8,357 $26,000
Q4 2021 Feb 14, 2022	BUY	$4.0 - $12.68 $13,984 - $44,329	3,496 Added 1748.0%	3,696 $16,000
Q3 2021 Nov 15, 2021	BUY	$5.32 - $9.65 $1,064 - $1,930	200 New	200 $2,000

37.5K

Ticker EVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 23,977,900
Market Cap $71.2M
Description
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Ph...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.